Display options
Cite
Ouyang DS, Huang WH, Chen D, et al. Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chin Med. 2016;11:11doi: 10.1186/s13020-016-0083-z.
Ouyang, D. S., Huang, W. H., Chen, D., Zhang, W., Tan, Z. R., Peng, J. B., Wang, Y. C., Guo, Y., Hu, D. L., Xiao, J., & Chen, Y. (2016). Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chinese medicine, 1111. https://doi.org/10.1186/s13020-016-0083-z
Ouyang, Dong-Sheng, et al. "Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro." Chinese medicine vol. 11 (2016): 11. doi: https://doi.org/10.1186/s13020-016-0083-z
Ouyang DS, Huang WH, Chen D, Zhang W, Tan ZR, Peng JB, Wang YC, Guo Y, Hu DL, Xiao J, Chen Y. Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chin Med. 2016 Mar 22;11:11. doi: 10.1186/s13020-016-0083-z. eCollection 2016. PMID: 27006687; PMCID: PMC4802617.
Copy Download .nbib Format: NLM
Share it on

Chin Med. 2016 Mar 22;11:11. doi: 10.1186/s13020-016-0083-z. eCollection 2016.

Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro.

Chinese medicine

Dong-Sheng Ouyang, Wei-Hua Huang, Dan Chen, Wei Zhang, Zhi-Rong Tan, Jing-Bo Peng, Yi-Cheng Wang, Ying Guo, Dong-Li Hu, Jian Xiao, Yao Chen

Affiliations

  1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, 410078 Hunan China ; Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, 410078 Hunan China.
  2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, 410078 Hunan China.
  3. Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, 410078 Hunan China.
  4. Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan China.

PMID: 27006687 PMCID: PMC4802617 DOI: 10.1186/s13020-016-0083-z

Abstract

BACKGROUND: Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA for treating cardiovascular disorders. The roles of cytochrome P450 enzymes (CYPs) in the metabolism of STS have remained unclear. This study aims to screen the main CYPs for metabolism of STS and study their interactions in vitro.

METHODS: Seven major CYPs were screened for metabolism of STS by human liver microsomes (HLMs) or recombinant CYP isoforms. Phenacetin (CYP1A2), coumarin (CYP2A6), tolbutamide (CYP2C9), metoprolol (CYP2D6), chlorzoxazone (CYP2E1), S-mephenytoin (CYP2C19), and midazolam (CYP3A4) were used as probe substrates to determine the potential of STS in affecting CYP-mediated phase I metabolism in humans. Enzyme kinetic studies were performed to investigate the modes of inhibition of the enzyme-substrate interactions by GraphPad Prism Enzyme Kinetic 5 Demo software.

RESULTS: Sodium tanshinone IIA sulfonate inhibited the activity of CYP3A4 in a dose-dependent manner by the HLMs and CYP3A4 isoform. The K m and V max values of STS were 54.8 ± 14.6 µM and 0.9 ± 0.1 nmol/mg protein/min, respectively, for the HLMs and 7.5 ± 1.4 µM and 6.8 ± 0.3 nmol/nmol P450/min, respectively, for CYP3A4. CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19 showed minimal or no effects on the metabolism of STS.

CONCLUSION: This in vitro study showed that STS mainly inhibited the activities of CYP3A4.

References

  1. Phytomedicine. 2010 Sep;17(11):868-75 - PubMed
  2. Xenobiotica. 2009 Jul;39(7):508-13 - PubMed
  3. Chem Biol Interact. 2013 Aug 25;204(3):140-3 - PubMed
  4. Pharm Biol. 2015;53(12):1752-8 - PubMed
  5. Life Sci. 2015 Dec 1;142:8-18 - PubMed
  6. Xenobiotica. 2003 Jun;33(6):603-13 - PubMed
  7. Pharm Biol. 2016;54(4):701-4 - PubMed
  8. Antivir Ther. 2014;19(8):793-8 - PubMed
  9. Drug Metab Pharmacokinet. 2002;17(2):150-6 - PubMed
  10. Biomed Chromatogr. 2014 Feb;28(2):197-203 - PubMed
  11. Life Sci. 2004 Jan 2;74(7):885-96 - PubMed
  12. Tumour Biol. 2013 Apr;34(2):649-60 - PubMed
  13. Chem Pharm Bull (Tokyo). 2007 May;55(5):753-6 - PubMed
  14. Int J Cardiol. 2015 Mar 1;182:329-33 - PubMed
  15. Antimicrob Agents Chemother. 2009 Feb;53(2):541-51 - PubMed
  16. Arch Pharm Res. 2012 Aug;35(8):1457-64 - PubMed
  17. Drug Metab Dispos. 2001 Mar;29(3):217-22 - PubMed
  18. PLoS One. 2014 Nov 26;9(11):e113819 - PubMed
  19. J Pharmacol Exp Ther. 1996 Apr;277(1):321-32 - PubMed
  20. Support Care Cancer. 2007 Mar;15(3):251-7 - PubMed
  21. Int J Biol Macromol. 2013 Jul;58:258-62 - PubMed
  22. Int Immunopharmacol. 2015 Sep;28(1):382-9 - PubMed
  23. Transpl Int. 2012 Apr;25(4):471-80 - PubMed
  24. Biomed Chromatogr. 2007 Nov;21(11):1172-9 - PubMed
  25. Drug Metab Rev. 2003 Feb;35(1):35-98 - PubMed
  26. Acta Pharmacol Sin. 2003 Oct;24(10):1033-8 - PubMed
  27. J Chromatogr A. 2013 May 3;1288:28-34 - PubMed
  28. Drug Metab Pharmacokinet. 2013;28(4):362-71 - PubMed
  29. Xenobiotica. 2009 May;39(5):382-90 - PubMed
  30. Molecules. 2011 Aug 29;16(9):7344-56 - PubMed
  31. PLoS One. 2012;7(7):e42138 - PubMed
  32. Atherosclerosis. 2012 Jan;220(1):3-10 - PubMed
  33. J Ethnopharmacol. 2013 Jan 9;145(1):152-61 - PubMed
  34. Int J Mol Med. 2015 Apr;35(4):1026-32 - PubMed
  35. Fitoterapia. 2015 Jan;100:174-8 - PubMed
  36. J Ethnopharmacol. 2014 Sep 11;155(2):1236-42 - PubMed

Publication Types